Prostate Cancer Bone Metastases Blocked with HIV Drug in Mice

Prostate Cancer Bone Metastases Blocked with HIV Drug in Mice
shutterstock_128569904Lethal bone metastases derived from prostate cancer may be readily prevented with a drug approved to treat HIV, according to new research from the laboratory of Richard Pestell, MD, PhD, MBA, at Thomas Jefferson University. The team found prostate cancer and HIV share a common receptor known as CCR5 and that blocking CCR5 reduces prostate cancer metastases in mouse models of disease. "Clinical trials of CCR5 inhibitors may warrant consideration in patients with CCR5 activation in their tumors," wrote Dr. Pestell and lead author Dr. Daniela Sicoli in "CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines," published in Cancer Research. The team's work was motivated by previous studies in Dr. Pestell's laboratory that identified CCR5 as a key component in the spread of breast cancer to the lungs: CCR5 acted as a magnet to the lungs for breast cancer cells. Since the team noticed similar behavior of prostate cancer cells attracted to bone and brain, they were interested in a possible connection between CCR5 and prostate cancer metastases. Research was not so simple, however, as no im
Subscribe or to access all post and page content.

Tagged , , , , .

Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Leave a Comment

Your email address will not be published. Required fields are marked *